Feasibility of Non-invasive Glucose Monitoring by Using Photothermal Deflectometry

Healthy Clinical Trial

Official title:

Feasibility of Non-invasive Glucose Monitoring by Using Photothermal Deflectometry

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06088615
• Other study ID #: IfDT-2325-DE
• Secondary ID: CIV-23-08-043757
• Status: Recruiting
• Start date: November 8, 2023
• Est. completion date: February 1, 2024

Study information

• Verified date: October 2023
• Source: Diamontech AG
• Contact: Thorsten Lubinski
• Phone: +49 30 27587051
• Email: thorsten.lubinski[@]diamontech.de
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study aims to evaluate the feasibility of non-invasive glucose monitoring by using photothermal deflectometry in the interstitial fluid of the skin on the wrist of subjects with diabetes mellitus type 1 and 2.

Description:

The investigation is designed as an open, monocentric, non-randomized, single-arm, explorative study in adult subjects without diabetes and with type 1 or 2 diabetes mellitus (any therapy form). The clinical investigation will be performed in an outpatient setting on up to three study days with up to 36 subjects. At least 6 subjects shall be included in each of the three subgroups (type 1 diabetes, type 2 diabetes, no diabetes)

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 36
• Est. completion date: February 1, 2024
• Est. primary completion date: February 1, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Clinical diagnosis of type 1 OR type 2 diabetes OR no diabetes
• For subjects with diabetes: glycated haemoglobin (HbA1c) <10%
• Age = 18 years
• Male or female or diverse
• An understanding of and willingness to follow the protocol
• Signed informed consent

Exclusion Criteria:

• Severe hypoglycemia resulting in seizure or loss of consciousness in the 3 months prior to enrollment
• Hypoglycemia unawareness
• Have extensive skin changes/diseases at the proposed measurement site (wrist and upper arm for FreeStyle Libre 3) that could interfere with the accuracy of glucose measurements.
• Female subjects: pregnancy, lactation period, lack of a negative pregnancy test (except in case of menopause, sterilization or hysterectomy)
• Serious acute or chronic disease besides diabetes mellitus or an anamnesis which might, in the opinion of the investigator, pose a risk to the subject, e.g. seizure disorder, adrenal disorder, dialysis for renal failure, cystic fibrosis, active infection
• Severe diabetes related complications (i.e. macro angiopathy, severe micro angiopathy, severe neuro-, retino- or nephropathy) when unstable (defined by event or increasing symptoms in the last 6 months) or with insufficient therapy
• Known severe tape reactions or allergies
• Any incapacity or general condition that, in the opinion of the investigator, prevents adequate compliance with the study procedures, e.g. mental or visual incapacity, tremor, language barriers, alcohol or drug misuse
• Not able to understand, write or read German
• Dependency from the sponsor or the clinical investigator

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus Type 1
• Diabetes Mellitus Type 2
• Diabetes Mellitus, Type 1
• Diabetes Mellitus, Type 2
• Healthy

Locations

Country	Name	City	State
Germany	Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm	Ulm	Baden-Württemberg

Sponsors (2)

Lead Sponsor	Collaborator
Diamontech AG	Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Accuracy of non-invasive glucose measurement in comparison to invasive glucose measurement	The accuracy of glucose values determined by D-Base 2.0 Prototype B in comparison with Contour Next (CNXT) values (non-invasive vs invasive glucose measurement) is determined by the following specific analysis: Number and percentage of D-Base 2.0 Prototype B results within ±15 mg/dl or ±15% as well as ±20 mg/dl or ±20% and ±30 mg/dl or ±30% of mean CNXT results for mean CNXT results <100 mg/dl or =100 mg/dl, respectively	3-13 days per subject